Posted inCampaigning Community News International Medicines News PrEP Prevention Research Treatment Gilead to support generic lenacapavir in low-income nations Posted by By Tom Hayes-Isaacs 2024-10-08 Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inCampaigning International News Prevention Activists demand global access to HIV prevention drug Posted by By Tom Hayes-Isaacs 2024-09-24 HIV and sexual health activists protested today at Gilead Sciences' London Office demanding the company…
Posted inNews PrEP Prevention Research Twice-yearly lenacapavir 89% more effective than Truvada Posted by By Tom Hayes-Isaacs 2024-09-24 New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inInternational News PrEP Prevention Concern as PrEP supplies run low in Australia Posted by By Tom Hayes-Isaacs 2024-09-04 Australian sexual health and HIV organisations are sending out reminders for PrEP users to "plan…
Posted inHealthcare International News PrEP Prevention PrEP approved to prevent HIV in Japan Posted by By Tom Hayes-Isaacs 2024-08-30 Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.
Posted inNews PrEP Prevention UK’s first Digital PrEP service starts in East Sussex Posted by By Tom Hayes-Isaacs 2024-08-08 A new digital PrEP service has just launched in East Sussex, making it easier for…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research Cabotegravir PrEP injection is safe during pregnancy Posted by By Tom Hayes-Isaacs 2024-07-30 The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…
Posted inConferences Healthcare Medicines News PrEP Prevention Twice-yearly lenacapavir injection sees zero HIV infections in trial Posted by By Tom Hayes-Isaacs 2024-07-25 AIDS 2024 Conference Coverage Preliminary findings from the phase III PURPOSE 1 trial revealed that…